Jessica Shipley, James Beharry, Wei Yeh, Nabil Seery, Yi Chao Foong, Darshini Ayton, Pakeeran Siriratnam, Tracie Tan, Heidi Beadnall, Joshua Barton, Francesca Bridge, Robb Wesselingh, Lisa Taylor, Louise Rath, Jodi Haartsen, Mohammad Gadi, Cassie Nesbitt, Michael Zhong, Victoria Cushing, Fiona McKay, Julia Morahan, Benjamin Peter Trewin, Izanne Roos, Mark Marriott, Ai-Lan Nguyen, Emma Downey, Joanne Crosby, Julian Bosco, Jennifer Taylor, Lauren Giles, Nevin John, Ernest Butler, Anneke van der Walt, Helmut Butzkueven, Stefan Blum, Marion Simpson, Mark Slee, Sudarshini Ramanathan, Todd Hardy, Richard A L Macdonell, Katherine Buzzard, Deborah F Mason, Jeannette Lechner-Scott, Trevor J Kilpatrick, Tomas Kalincik, Bruce V Taylor, Simon A Broadley, Stephen Reddel, Douglas Johnson, Mastura Monif, the MS Interest Group, Australian and New Zealand Association of Neurologists
{"title":"澳大利亚和新西兰多发性硬化症管理的共识建议：第2部分。","authors":"Jessica Shipley, James Beharry, Wei Yeh, Nabil Seery, Yi Chao Foong, Darshini Ayton, Pakeeran Siriratnam, Tracie Tan, Heidi Beadnall, Joshua Barton, Francesca Bridge, Robb Wesselingh, Lisa Taylor, Louise Rath, Jodi Haartsen, Mohammad Gadi, Cassie Nesbitt, Michael Zhong, Victoria Cushing, Fiona McKay, Julia Morahan, Benjamin Peter Trewin, Izanne Roos, Mark Marriott, Ai-Lan Nguyen, Emma Downey, Joanne Crosby, Julian Bosco, Jennifer Taylor, Lauren Giles, Nevin John, Ernest Butler, Anneke van der Walt, Helmut Butzkueven, Stefan Blum, Marion Simpson, Mark Slee, Sudarshini Ramanathan, Todd Hardy, Richard A L Macdonell, Katherine Buzzard, Deborah F Mason, Jeannette Lechner-Scott, Trevor J Kilpatrick, Tomas Kalincik, Bruce V Taylor, Simon A Broadley, Stephen Reddel, Douglas Johnson, Mastura Monif, the MS Interest Group, Australian and New Zealand Association of Neurologists","doi":"10.5694/mja2.52577","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system with rapidly evolving treatment options and strategies. An iterative modified Delphi process was used to develop 80 consensus recommendations for the management of MS in Australia and New Zealand. Part 1 of these guidelines includes recommendations related to selection of initial disease-modifying therapy (DMT) for MS, assessments before commencing DMT, monitoring disease activity on DMT, switching DMT, and discontinuing DMT.</p>\n </section>\n \n <section>\n \n <h3> Main recommendations</h3>\n \n <p>This article, Part 2, covers recommendations related to risk mitigation during treatment with DMT, managing DMT in special situations (including pregnancy, postpartum, breastfeeding, active infection including COVID-19, and malignancy), general lifestyle measures for MS, acute MS relapses, and symptomatic treatments.</p>\n </section>\n \n <section>\n \n <h3> Changes in management as a result of the guidelines</h3>\n \n <p>Together with Part 1, this consensus statement provides practical guidance for clinicians involved in the care of adults (≥ 18 years old) with MS in Australia and New Zealand. A safe, effective and comprehensive approach to managing MS is crucial for improving long term outcomes and quality of life in individuals affected by MS.</p>\n </section>\n </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"222 7","pages":"365-371"},"PeriodicalIF":6.7000,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2\",\"authors\":\"Jessica Shipley, James Beharry, Wei Yeh, Nabil Seery, Yi Chao Foong, Darshini Ayton, Pakeeran Siriratnam, Tracie Tan, Heidi Beadnall, Joshua Barton, Francesca Bridge, Robb Wesselingh, Lisa Taylor, Louise Rath, Jodi Haartsen, Mohammad Gadi, Cassie Nesbitt, Michael Zhong, Victoria Cushing, Fiona McKay, Julia Morahan, Benjamin Peter Trewin, Izanne Roos, Mark Marriott, Ai-Lan Nguyen, Emma Downey, Joanne Crosby, Julian Bosco, Jennifer Taylor, Lauren Giles, Nevin John, Ernest Butler, Anneke van der Walt, Helmut Butzkueven, Stefan Blum, Marion Simpson, Mark Slee, Sudarshini Ramanathan, Todd Hardy, Richard A L Macdonell, Katherine Buzzard, Deborah F Mason, Jeannette Lechner-Scott, Trevor J Kilpatrick, Tomas Kalincik, Bruce V Taylor, Simon A Broadley, Stephen Reddel, Douglas Johnson, Mastura Monif, the MS Interest Group, Australian and New Zealand Association of Neurologists\",\"doi\":\"10.5694/mja2.52577\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system with rapidly evolving treatment options and strategies. An iterative modified Delphi process was used to develop 80 consensus recommendations for the management of MS in Australia and New Zealand. Part 1 of these guidelines includes recommendations related to selection of initial disease-modifying therapy (DMT) for MS, assessments before commencing DMT, monitoring disease activity on DMT, switching DMT, and discontinuing DMT.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Main recommendations</h3>\\n \\n <p>This article, Part 2, covers recommendations related to risk mitigation during treatment with DMT, managing DMT in special situations (including pregnancy, postpartum, breastfeeding, active infection including COVID-19, and malignancy), general lifestyle measures for MS, acute MS relapses, and symptomatic treatments.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Changes in management as a result of the guidelines</h3>\\n \\n <p>Together with Part 1, this consensus statement provides practical guidance for clinicians involved in the care of adults (≥ 18 years old) with MS in Australia and New Zealand. A safe, effective and comprehensive approach to managing MS is crucial for improving long term outcomes and quality of life in individuals affected by MS.</p>\\n </section>\\n </div>\",\"PeriodicalId\":18214,\"journal\":{\"name\":\"Medical Journal of Australia\",\"volume\":\"222 7\",\"pages\":\"365-371\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2025-02-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Journal of Australia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.5694/mja2.52577\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of Australia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.5694/mja2.52577","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2
Introduction
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system with rapidly evolving treatment options and strategies. An iterative modified Delphi process was used to develop 80 consensus recommendations for the management of MS in Australia and New Zealand. Part 1 of these guidelines includes recommendations related to selection of initial disease-modifying therapy (DMT) for MS, assessments before commencing DMT, monitoring disease activity on DMT, switching DMT, and discontinuing DMT.
Main recommendations
This article, Part 2, covers recommendations related to risk mitigation during treatment with DMT, managing DMT in special situations (including pregnancy, postpartum, breastfeeding, active infection including COVID-19, and malignancy), general lifestyle measures for MS, acute MS relapses, and symptomatic treatments.
Changes in management as a result of the guidelines
Together with Part 1, this consensus statement provides practical guidance for clinicians involved in the care of adults (≥ 18 years old) with MS in Australia and New Zealand. A safe, effective and comprehensive approach to managing MS is crucial for improving long term outcomes and quality of life in individuals affected by MS.
期刊介绍：
The Medical Journal of Australia (MJA) stands as Australia's foremost general medical journal, leading the dissemination of high-quality research and commentary to shape health policy and influence medical practices within the country. Under the leadership of Professor Virginia Barbour, the expert editorial team at MJA is dedicated to providing authors with a constructive and collaborative peer-review and publication process. Established in 1914, the MJA has evolved into a modern journal that upholds its founding values, maintaining a commitment to supporting the medical profession by delivering high-quality and pertinent information essential to medical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
